Wang Bei, Zhao Limiao, Chen Dandan
Institute of Integration of Traditional Chinese and Western Medicine, the Hospital Affiliated to Jiangnan University, Wuxi, People's Republic of China.
Department of Education, School of Humanities, Jiangnan University, Wuxi, People's Republic of China.
J Inflamm Res. 2022 Jul 15;15:4013-4025. doi: 10.2147/JIR.S362606. eCollection 2022.
Coactosin-like protein (COTL1) was first identified as protein that binds 5-lipoxygenase and F-actin; its functions in tumors remain unknown. COTL1 could inhibit the proliferation of breast cancer (BRCA) in vivo and in vitro; however, online public databases including UALCAN and Kaplan-Meier plotter showed high COTL1 expression in breast cancer tissue, which was correlated with poor prognosis. Therefore, we studied the role of COTL1 expression in human breast cancer and its use in determining clinical prognosis.
We first used the UALCAN database and immunohistochemical analysis to elucidate COTL1 expression in BRCA. We then performed Kaplan-Meier plotting and immunohistochemical analysis to assess prognosis in BRCA in relation to COTL1 expression. Finally, we used the CancerSEA and LinkedOmics databases to evaluate the function of COTL1 in BRCA. The TIMER and TISIDB databases were used to evaluate the association between COTL1 expression and immune cell infiltration in BRCA.
UALCAN and immunohistochemical analysis showed that COTL1 was highly expressed in breast cancer. Furthermore, high COTL1 expression was correlated with poor prognosis in BRCA. We also found that COTL1 is involved in immune response via the CancerSEA and LinkedOmics databases. The TIMER and TISIDB databases showed that high COTL1 expression was correlated with immune cell infiltration.
COTL1 expression was higher in breast cancer tissues than in normal tissues, and high COTL1 expression was correlated with poor prognosis and immune cell infiltration. These results provide a basis for the development of applications of COTL1 in determining the prognosis of breast cancer and its treatment.
类肌动蛋白结合蛋白（COTL1）最初被鉴定为一种能结合5-脂氧合酶和F-肌动蛋白的蛋白质；其在肿瘤中的功能尚不清楚。COTL1在体内和体外均可抑制乳腺癌（BRCA）的增殖；然而，包括UALCAN和Kaplan-Meier plotter在内的在线公共数据库显示，乳腺癌组织中COTL1表达较高，且与预后不良相关。因此，我们研究了COTL1表达在人类乳腺癌中的作用及其在确定临床预后中的应用。
我们首先使用UALCAN数据库和免疫组织化学分析来阐明BRCA中COTL1的表达。然后进行Kaplan-Meier绘图和免疫组织化学分析，以评估BRCA中与COTL1表达相关的预后。最后，我们使用CancerSEA和LinkedOmics数据库来评估COTL1在BRCA中的功能。使用TIMER和TISIDB数据库来评估COTL1表达与BRCA中免疫细胞浸润之间的关联。
UALCAN和免疫组织化学分析表明，COTL1在乳腺癌中高表达。此外，COTL1高表达与BRCA的不良预后相关。我们还通过CancerSEA和LinkedOmics数据库发现COTL1参与免疫反应。TIMER和TISIDB数据库显示，COTL1高表达与免疫细胞浸润相关。
乳腺癌组织中COTL1表达高于正常组织，COTL1高表达与不良预后和免疫细胞浸润相关。这些结果为开发COTL1在确定乳腺癌预后及其治疗中的应用提供了依据。
